BioSpace News Archive

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution.

Sernova Corp., a clinical-stage company and leader in regenerative medicine cell therapeutics, announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE of 2,709,800 common shares of the Company at a price of $2.50 per share for total proceeds of $6,774,500.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced participation in upcoming investor conferences.

Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the acceptance of a late-breaking oral presentation and an additional poster presentation, including Phase 2a data for AZP-3601, its lead therapeutic peptide for hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference.

Merus N.V. (Nasdaq: MRUS), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET.

Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the company will participate at the 44th European Society for Clinical Nutrition and Metabolism Congress taking place September 3-6, 2022, in Vienna.